KLSE (MYR): ALPHA (0303)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.35
Today's Change
0.00 (0.00%)
Day's Change
0.35 - 0.35
Trading Volume
80,700
Market Cap
1,701 Million
NOSH
4,860 Million
Latest Quarter
31-Aug-2024 [#1]
Announcement Date
21-Oct-2024
Next Quarter
30-Nov-2024
Est. Ann. Date
18-Mar-2025
Est. Ann. Due Date
29-Jan-2025
QoQ | YoY
2.66% | 0.00%
Revenue | NP to SH
168,985.000 | 54,192.000
RPS | P/RPS
3.48 Cent | 10.07
EPS | P/E | EY
1.12 Cent | 31.39 | 3.19%
DPS | DY | Payout %
1.10 Cent | 3.14% | 98.43%
NAPS | P/NAPS
0.04 | 8.75
QoQ | YoY
36.12% | null%
NP Margin | ROE
32.84% | 27.88%
F.Y. | Ann. Date
31-Aug-2024 | 21-Oct-2024
Latest Audited Result
31-May-2024
Announcement Date
30-Sep-2024
Next Audited Result
31-May-2025
Est. Ann. Date
30-Sep-2025
Est. Ann. Due Date
27-Nov-2025
Revenue | NP to SH
167,586.000 | 52,933.000
RPS | P/RPS
3.45 Cent | 10.15
EPS | P/E | EY
1.15 Cent | 32.13 | 3.11%
DPS | DY | Payout %
0.70 Cent | 2.00% | 64.27%
NAPS | P/NAPS
0.04 | 8.75
YoY
null%
NP Margin | ROE
32.26% | 27.23%
F.Y. | Ann. Date
31-May-2024 | 17-Jul-2024
Revenue | NP to SH
171,980.000 | 57,524.000
RPS | P/RPS
3.54 Cent | 9.89
EPS | P/E | EY
1.20 Cent | 29.57 | 3.38%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
8.67% | null%
NP Margin | ROE
34.76% | 29.59%
F.Y. | Ann. Date
31-Aug-2024 | 21-Oct-2024
Trailing 4 Quarters | Trailing 8 Quarters | |||
---|---|---|---|---|
Available Quarters | 4 Quarters | 8 Quarters | ||
Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Total Positive Profit Years | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Continuous Quarters Of Profit Growth | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 4 / 4 | 100.00% | 4 / 8 | 50.00% |
Total Dividend Years | 3 / 4 | 75.00% | 3 / 8 | 38.00% |
Continuous Quarters Of Dividend | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 1 / 4 | 25.00% | 1 / 8 | 12.50% |
Average ROE | 14.61% | 7.30% | ||
Average Net Profit Margin | 32.89% | 16.44% |
Last 5 Financial Years | Last 10 Financial Years | |||
---|---|---|---|---|
Available Years | 5 Years | 10 Years | ||
Continuous Quarters Of Revenue Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Positive Profit Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Positive Profit | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Profit Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Adjusted EPS Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Total Dividend Years | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Dividend | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Continuous Quarters Of Dividend Growth | 0 / 2 | 0.00% | 0 / 2 | 0.00% |
Continuous Quarters Of Adjusted Dps Growth | 1 / 2 | 50.00% | 1 / 2 | 50.00% |
Average ROE | 13.62% | 13.62% | ||
Average Net Profit Margin | 16.13% | 16.13% |
T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
---|---|---|---|---|---|
Revenue | 168,985 | 171,980 | 167,586 | 83,793 | 83,793 |
NP to SH | 54,192 | 57,524 | 52,933 | 26,466 | 26,466 |
Dividend | 53,338 | 87,479 | 34,019 | 17,009 | 17,009 |
Adjusted EPS | 1.12 | 1.20 | 1.15 | 0.58 | 0.58 |
Adjusted DPS | 1.10 | 1.80 | 0.70 | 0.35 | 0.35 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
---|---|---|---|---|---|
Revenue | -8.02% | 0.00% | 0.00% | 1.77% | 103.54% |
NP to Owner | 2.66% | 0.00% | 0.00% | 6.15% | 112.30% |
Dividend | 0.00% | 0.00% | 0.00% | 64.01% | 228.02% |
Adjusted EPS | 3.45% | 0.00% | 0.00% | 7.06% | 114.11% |
Adjusted DPS | 0.00% | 0.00% | 0.00% | 64.01% | 228.02% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.83% | 101.67% | 101.67% | 2.62% | 105.24% | 105.24% | 0.00% | 100.00% | 100.00% |
NP to Owner | 2.38% | 104.76% | 104.76% | 8.67% | 117.35% | 117.35% | 0.00% | 100.00% | 100.00% |
Dividend | 56.79% | 213.57% | 213.57% | 157.14% | 414.29% | 414.29% | 0.00% | 100.00% | 100.00% |
Adjusted EPS | -2.61% | 94.78% | 94.78% | 4.35% | 108.70% | 108.70% | 0.00% | 100.00% | 100.00% |
Adjusted DPS | 57.14% | 214.29% | 214.29% | 157.14% | 414.29% | 414.29% | 0.00% | 100.00% | 100.00% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Don’t worry, revenue from Indonesia, China and the Philippines will offset the increased administrative costs
2 weeks ago
In the AGM, Alpha had mentioned that Alhaya, the 51.0% owned specialists centre of Alpha IVF, is expected to cater for the largely untapped Muslim market, both domestically and internationally.
2 weeks ago
This company is turning into blue chip soon, if they keep on expanding and execute their dividend payment plan
2 weeks ago
5. ORDINARY RESOLUTION 5
Description Authority To Directors Pursuant To Sections 75 And 76 Of The Companies Act 2016.
what is this
2 weeks ago
@stevenckheng. It's a provision that allows the directors of a company to issue new shares without seeking prior approval from shareholders for each issuance
2 weeks ago
The benefit of this resolution is to enable directors to effectively manage fundraising efforts or issue new shares within a predetermined range approved by shareholders to support business operations, strategic partnerships and expansion plans
2 weeks ago
Quick review from ALPHA AGM last friday
https://klse.i3investor.com/web/blog/detail/OddesyOne/2024-11-01-story-h472908510-Top_5_Things_I_Learned_from_Alpha_IVF_s_2024_AGM
2 weeks ago
Alhaya, pusat pakar Alpha IVF, dijangka memenuhi sebahagian besar pasaran Muslim di dalam dan di luar negara. Selain itu, Alhaya terletak di Hospital Pakar KPJ Damansara 2, dan ini akan memanfaatkan Alpha IVF dgn aliran pelanggan berpotensi yg byk
2 weeks ago
ALPHA will be the SEA regional leader in fertility care with more expansion into Indonesia and the Philippines, stay for the long term growth & dividend
2 weeks ago
People nowadays are conscious of the fertility care, this is one of the drivers of their long term growth
2 weeks ago
Heard that ALPHA is inventing a machine called "SHOOGLE" that mimics the womb and will apply for a patent for the machine
2 weeks ago
Alhaya, Alpha IVF’s 51%-owned specialist center, is set to serve the largely untapped Muslim market both locally and internationally. Located within KPJ Damansara Specialist Hospital 2, this partnership enables Alpha IVF to tap into a strong client base by collaborating closely with KPJ.
2 weeks ago
Alpha IVF Group Berhad stands out for its use of cutting-edge technology in reproductive health. Their advanced techniques, like preimplantation genetic testing and precision lab facilities, really put them at the forefront of fertility treatment in the region.
2 weeks ago
The success rates achieved by Alpha IVF are among the best in the industry, which speaks volumes about their expertise and dedication to patient outcomes.
2 weeks ago
Alpha is the top Fertility Hospital of the Year, of course success rate are high with averaging up to 87.5%, and the successful delivery of more than 7,000 IVF babies
2 weeks ago
The company has won many world firsts in the field of fertility. Consider it's a strong moat
2 weeks ago
The growing prevalence of infertility among couples, ongoing advancements in IVF technology, and changing societal attitudes toward family have all driven the rising demand for IVF services, giving ALPHA a highly promising outlook !
1 week ago
ALPHA provides a comprehensive range of fertility services under one roof, which really simplifies things for patients. From IVF and ICSI to cryopreservation and genetic testing, their wide array of services makes them a strong threat for the competitors in the market
1 week ago
Fertility specialist Alpha IVF continues to deliver remarkably high pregnancy success rates, superior margins and canny focus on target markets amid rising affluence and low IVF penetration rates in the region position ahead of peers.
1 week ago
Let's follow the boss buying 😁
https://klse.i3investor.com/web/insider/detail/D_182262_1566210842
1 week ago
Nice, Alpha IVF scales up in Singapore with 3 new specialists
https://www.nst.com.my/business/corporate/2024/11/1133223/alpha-ivf-scales-singapore-3-new-specialists
1 week ago
bagus, Dato Dr Lee kumpul lagi
https://klse.i3investor.com/web/insider/detail/D_182300_1081034373
1 week ago
Alpha IVF Singapore now has one of the largest IVF teams in the country, capable of handling up to 1,000 IVF cycles annually which aligns with the Singaporean government's efforts to address the nation's declining birth rate by providing high-quality fertility services.
1 week ago
Adding renowned specialists to its team can boost Alpha IVF’s reputation as a leading fertility clinic in Singapore, further building trust among patients. Nice move 👍
6 days ago
Singapore is a good market to tap in as the infertility affects approx 15% of the couples in Singapore according to NUHS
6 days ago
A larger team with diverse specializations fosters opportunities for clinical research and innovation in reproductive medicine. This can lead to advancements in fertility treatments and position Alpha IVF as a thought leader in the field
2 days ago
Alpha IVF Group is a leading provider of reproductive technology solutions to individuals and couples dedicated to achieving their support. Their advanced technology provides personalized and comprehensive treatment supported by a team of experienced professionals. It has four IVF fertility centers in Malaysia and Singapore. It was also awarded the prestigious Fertility Hospital of the Year award at the Asia Awards 2024. It has made outstanding contributions to patient care and innovation in the healthcare industry across Asia.
1 day ago
Infertility has become a common issue worldwide, therefore the demand for IVF will definitely increase
1 day ago
ALPHA provides a comprehensive range of fertility services under one roof, which really simplifies things for patients. From IVF and ICSI to cryopreservation and genetic testing, their wide array of services makes them a one-stop solution for fertility treatment.
11 hours ago
Alpha IVF not putting all eggs in one basket, eyes regional expansion
https://theedgemalaysia.com/node/733476
10 hours ago
With a goal to become a regional player, Alpha IVF’s growth strategy will also be driven by the establishment of new IVF centres in Malaysia, as well as Indonesia, China and the Philippines. With this expansion plan, Alpha IVF will be transformed from mainly a national player in the IVF industry to a major regional one
9 hours ago
soon9913
Opening new outlets required time to grow... Long run is good. Short term profit should be reducing due to higher costs I.e rental, staff costs and etc
3 weeks ago